TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

January 12, 2026 UCBN News, Syndication Comments Off on TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

WESTMINSTER, Colo.–(BUSINESS WIRE)–TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and ful
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Related Articles

No Picture
News

Study Results Show Medical Cannabis Use Tied to Improved Quality of Life for Patients Experiencing Neurological and Pain-Related Ailments

September 6, 2022 UCBN News Comments Off on Study Results Show Medical Cannabis Use Tied to Improved Quality of Life for Patients Experiencing Neurological and Pain-Related Ailments

COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Recent findings indicate that medical cannabis consumption can improve the quality of life for those who could not find reprieve from traditional methods, according to a large online study conducted by Realm […]